Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 12.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,667 shares of the biotechnology company’s stock after selling 3,647 shares during the period. New York Life Investment Management LLC’s holdings in Exelixis were worth $888,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund lifted its stake in Exelixis by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after purchasing an additional 354 shares during the last quarter. Denali Advisors LLC lifted its stake in Exelixis by 49.8% during the fourth quarter. Denali Advisors LLC now owns 12,631 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 4,200 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Exelixis by 20.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company’s stock valued at $71,828,000 after purchasing an additional 366,141 shares during the last quarter. Amalgamated Bank lifted its stake in Exelixis by 1.7% during the fourth quarter. Amalgamated Bank now owns 142,147 shares of the biotechnology company’s stock valued at $4,733,000 after purchasing an additional 2,435 shares during the last quarter. Finally, Prasad Wealth Partners LLC acquired a new stake in Exelixis during the fourth quarter valued at approximately $533,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Down 0.4 %

Shares of EXEL opened at $38.55 on Tuesday. The company’s fifty day moving average is $34.63 and its 200-day moving average is $31.78. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $39.30. The firm has a market cap of $10.79 billion, a price-to-earnings ratio of 21.78, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on EXEL. Guggenheim restated a “buy” rating and set a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Citigroup boosted their price target on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $41.00 to $33.00 in a report on Friday, January 24th. UBS Group boosted their price target on shares of Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $36.00 to $40.00 in a report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 52,636 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 130,343 shares of company stock worth $4,789,234 in the last 90 days. 2.85% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.